Heather Bresch, chief executive officer of Mylan NV, speaks during a Bloomberg Television interview in New York, U.S., on Thursday, Aug. 6, 2015. Bresch discussed the generic drugmaker's second-quarter profit and share price, mergers and acquisitions in the pharmaceutical industry, the failed takeover bid for Mylan by Teva Pharmaceuticals Industries Ltd. and Mylan's own bid for Perrigo Co. Photographer: Chris Goodney/Bloomberg via Getty ImagesChris Goodney—Bloomberg via Getty Images
Last year’s scandal over Mylan’s 500% price hike of the EpiPen, a potentially lifesaving allergy treatment, tarnished Bresch’s reputation, but it didn’t hurt her business as much as some expected. The company grew revenue 18%, to more than $11 billion in 2016, and forecasts growth of up to 13% this year, in part thanks to its acquisition of Swedish drugmaker Meda. But the EpiPen debacle took its toll in other ways: The company coughed up a $465 million settlement fine, prompting profits to drop 43%.
For more on Bresch, read Fortune’s 2015 feature, “Why Wall Street Loves to Hate Mylan’s CEO" and "Why the CEO Behind the EpiPen Controversy Remains One of Fortune’s Most Powerful Women."
Company Financials (2016, or most recently completed fiscal year)
|Market Value as of 9/14/17 ($M)||17627.5|